Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non-small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834).
Miura S, Yamanaka T, Kato T, Ikeda S, Horinouchi H, Ichihara E, Kanazu M, Takiguchi Y, Tanaka K, Goto Y, Sata M, Hagiwara K, Okamoto H, Tanaka H. Miura S, et al. Among authors: ichihara e. Clin Lung Cancer. 2020 Nov;21(6):e592-e596. doi: 10.1016/j.cllc.2020.05.011. Epub 2020 May 21. Clin Lung Cancer. 2020. PMID: 32611505 Clinical Trial.
Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.
Zhang D, Ochi N, Takigawa N, Tanimoto Y, Chen Y, Ichihara E, Hotta K, Tabata M, Tanimoto M, Kiura K. Zhang D, et al. Among authors: ichihara e. Cancer Lett. 2011 Oct 28;309(2):228-35. doi: 10.1016/j.canlet.2011.06.006. Epub 2011 Jun 24. Cancer Lett. 2011. PMID: 21742432
Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402.
Nogami N, Hotta K, Segawa Y, Takigawa N, Hosokawa S, Oze I, Fujii M, Ichihara E, Shibayama T, Tada A, Hamada N, Uno M, Tamaoki A, Kuyama S, Ikeda G, Osawa M, Takata S, Tabata M, Tanimoto M, Kiura K. Nogami N, et al. Among authors: ichihara e. Acta Oncol. 2012 Jul;51(6):768-73. doi: 10.3109/0284186X.2011.648342. Epub 2012 Jan 27. Acta Oncol. 2012. PMID: 22283472 Clinical Trial.
JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation.
Harada D, Takigawa N, Ochi N, Ninomiya T, Yasugi M, Kubo T, Takeda H, Ichihara E, Ohashi K, Takata S, Tanimoto M, Kiura K. Harada D, et al. Among authors: ichihara e. Cancer Sci. 2012 Oct;103(10):1795-802. doi: 10.1111/j.1349-7006.2012.02363.x. Epub 2012 Jul 24. Cancer Sci. 2012. PMID: 22712764 Free PMC article.
Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer.
Hotta K, Suzuki E, Di Maio M, Chiodini P, Fujiwara Y, Takigawa N, Ichihara E, Reck M, Manegold C, Pilz L, Hisamoto-Sato A, Tabata M, Tanimoto M, Shepherd FA, Kiura K. Hotta K, et al. Among authors: ichihara e. Lung Cancer. 2013 Jan;79(1):20-6. doi: 10.1016/j.lungcan.2012.10.007. Epub 2012 Nov 17. Lung Cancer. 2013. PMID: 23164554 Review.
173 results